Phase II clinical trial of TS-1 + docetaxel (DTX) combination therapy (OGSG 0902) for geriatric patients with advanced / recurrent gastric cancer in the elderly.

Trial Profile

Phase II clinical trial of TS-1 + docetaxel (DTX) combination therapy (OGSG 0902) for geriatric patients with advanced / recurrent gastric cancer in the elderly.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jan 2017

At a glance

  • Drugs Docetaxel (Primary) ; Gimeracil/oteracil/tegafur (Primary)
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 21 Jan 2017 Primary endpoint ((Response Rate (RECIST)) has been met.
    • 21 Jan 2017 Results presented at the 2017 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top